New OTC medicines for fungal nail infections and verrucas have been launched in the UK by Galderma, Reckitt Benckiser and Vemedia, while new foot-care products have also been introduced by Blistex, Epitact and Dermatonics.

RB didn't get help from consumer perception survey to support argument that "All In One" label statement is not claim the product treats all cold and flu symptoms. Council of Better Business Bureaus' division dismisses survey as faulty but approves RB's argument. NAD attorneys conclude 15- and 6-second TV and video "superhero 'movie trailer'” ads did not include "a sufficiently proximate and prominent list of symptoms" to counter "distracting features."

Eli Nutrition fails in appeal of NAD review of claims for its TummyZen heartburn relief product, with a panel of the National Advertising Review Board concluding the firm overstated its product’s benefits.

Speakers at ICMAD’s regulatory workshop in New York stressed the importance of CBD testing in today’s highly uncertain climate for hemp-based cosmetics. While rigorous testing can drive up costs and slow the path to market, it also could significantly reduce chances of safety, regulatory or legal issues down the line.

Marketing CBD-containing cosmetics in today’s hazy legal and regulatory environment carries risks beyond what insurance carriers may be willing to take on. Kenneth Hegel of Cosmetic Insurance Services, a division of brokerage firm Frenkel & Company – an Epic Company, discusses the dilemma facing underwriters and criteria companies can meet to improve their insurance prospects.

The answer to the ‘why’ question can help clarify whether a company is marketing a cosmetic or an unapproved drug, FDA’s cosmetics office director advised attendees at ICMAD’s 38^th annual regulatory workshop in New York.

FDA final guidance on MUsTs for topically applied ingredients for OTC drug monograph affirms draft, not incorporating changes pushed by industry. CHPA says FDA’s MUsT study published recently finding sunscreen actives penetrate skin to bloodstream at higher levels than previously believed demonstrates "value" of test method.

"You need to demonstrate to the best of your ability that you can't get there with just the Drug Facts label," says ONDP Director Theresa Michele during presentation on the FDA office' work over the past year at Consumer Healthcare Products Association's annual regulations and science conference.

As FDA moves slow on allowing CBD as a dietary ingredient, a marijuana reform law is a near-term possibility and would cause a “nuclear shift” about cannabis regulation and sway agency's decision, says cannabidiol firm CV Sciences executive.

Supplement and food firms should "check to see if any ingredients they use may be affected or potentially contaminated by genetically engineered bio-synthesized ingredients,” said Jim Thomas, scientist and co-founder of ETC Group. Biotechnologies have emerged to yield ingredients for clean label products with organisms raised in ecosystems developed from processes that involve genetic engineering.

Panel discussions and public comments during FDA public meeting show industry sees agency, as it stated in draft NDI notification guidances published in 2011 and 2016, is allowing little room for innovation through making new ingredients available for use in VMS products. FDA says immense growth of the VMS market since DSHEA passed shows numerous products available in US contain substances that haven't been notified to the FDA with proof showing they are dietary ingredients and are safe for use.

"Can we maybe as an industry, and I guess the FDA, agree not to overcomplicate the NDI process in the sense that it's actually pretty easy to navigate the process and understand what you have," says Frank Jaksch, Chromadex co-founder and executive chairman. "I want to encourage companies to do the right thing," says Mark LeDoux, founder, CEO and chairman of Natural Alternatives Internationa. "Our firm spent millions of dollars and went through the front door of the FDA. … This is not a difficult process to do the right thing."

While acknowledging concerns about oxybenzone, Consumer Reports maintains the importance of sunscreen to help prevent skin cancer and says oxybenzone-containing offerings continue to test best when it comes to broad-spectrum protection and minimal SPF “variation.”